Mirzam

Quick links to important sections

Mirzam

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mirzam

Quick Facts

Property Description
Active ingredient Desogestrel (Prodrug to Etonogestrel)
Form Oral Tablet
Pharmacological class Synthetic Progestogen (Progestin)
Common use Contraception (Prevention of Pregnancy)
Origin Semi-synthetic Steroid (Derived from Gonane)

Mirzam's Identity: Definition and Contraceptive Type

Mirzam is an oral contraceptive agent, presented in the form of an oral tablet, used for the essential purpose of conception control. This medication is specifically classified as a Progestogen-Only Pill (POP), containing the single active hormonal substance, Desogestrel. The single-hormone formulation is a key differentiating factor, making it medically suitable for women who cannot use estrogen-containing products. Desogestrel's active metabolite exhibits high progestational selectivity compared to older progestins, underscoring its role as a targeted contraceptive option.

Chemical Composition: Desogestrel and Pharmacological Class

The core active ingredient is Desogestrel, a synthetic steroid that belongs to the third-generation class of Progestogens (Progestins). Desogestrel functions as a prodrug, meaning it is quickly converted by the body into its biologically potent form, etonogestrel. This conversion is crucial for the drug's activity. The drug is designed for targeted hormonal activity with minimal intrinsic androgenic effects, a characteristic of this third-generation compound.

General Principle: How Mirzam Achieves its Purpose

The general purpose of conception control is achieved through the potent action of etonogestrel, which acts as a progesterone receptor agonist. Its primary mechanism is the reliable inhibition of ovulation, preventing the release of an egg from the ovary. This effect is augmented by two secondary actions: inducing a significant thickening of the cervical mucus to impede sperm passage and causing alterations to the endometrium (uterine lining). These complementary actions ensure the continuous, systemic protection provided by this oral contraceptive agent.

What side effects are possible with Mirzam?

Possible Side Effects and Safety Information

Mirzam’s (Desogestrel) official safety profile is organized by regulatory authorities to classify adverse reactions based on their frequency and the affected bodily system, adhering strictly to government prescribing information.


Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how often they may occur:

  • Very Common (Affecting more than 1 in 10 users): Changes to menstrual bleeding patterns, including irregular bleeding or the complete absence of bleeding (amenorrhoea). This is most frequently observed during the first few months of use.
  • Common (Affecting 1 to 10 in 100 users): Headache, nausea, changes in mood (including depressed mood), decreased libido, acne, breast pain, and weight increase.
  • Uncommon (Affecting 1 to 10 in 1,000 users): Vaginal infection, contact lens intolerance, vomiting, hair loss (alopecia), dysmenorrhoea (painful menstruation), and ovarian cysts.

Serious Adverse Reactions

Official labels document rare but clinically significant adverse events that warrant specific attention. These include the potential for Venous Thromboembolism (VTE), Ectopic Pregnancy, and the occurrence of Hepatic Tumours (benign or malignant). Hypersensitivity reactions, such as Angioedema, are also noted in the regulatory documentation.

Safety Constraints and Considerations

The medicine is restricted or requires caution in individuals with certain pre-existing conditions as defined in the official prescribing information:

  • Severe Hepatic Disease: Mirzam is not recommended for use in individuals with current or past severe liver disease until liver function has returned to normal.
  • Thromboembolic Disorder: The medicine is contraindicated in individuals with active or a history of venous thromboembolism.
  • Malignancy: Safety constraints apply to individuals with known or suspected sex-steroid sensitive malignancies, such as breast carcinoma.

This structure formally establishes the spectrum of expected changes and serious risks, ensuring all factual safety information is conveyed according to official regulatory standards.

Overdose and Emergency Response

Overdose Manifestations and Acute Toxicity

Mirzam (Desogestrel) overdose is officially characterized by low acute toxicity and is not reported to cause serious life-threatening outcomes. Regulatory documents indicate that the acute risk for severe harmful effects following exposure to supratherapeutic doses is minimal.

The clinical signs and manifestations of overdose documented in official prescribing information include specific hormonal effects and general symptoms:

  • Nausea, Vomiting, and Drowsiness
  • Headache and Breast Tenderness
  • Vaginal Bleeding (often termed withdrawal bleeding)

A population-specific note in regulatory documentation is the potential for slight vaginal bleeding to occur in young girls (pre-pubertal patients) who have experienced an overdose.

Emergency Actions and Management

Regulatory authorities strictly require that a person seek immediate medical attention or contact a national poison control center immediately upon suspicion of overdose.

Urgent medical care is mandated if any sign of a severe complication is present. Get emergency medical treatment immediately for symptoms such as sudden severe chest pain, unexplained pain or swelling in a limb, or difficulty breathing.

The official management approach for Mirzam overdose is defined as symptomatic and supportive, as no specific antidote is known. This requires professional clinical evaluation and observation to manage any documented manifestations.

Therapeutic Uses of Mirzam

Quick Facts: Uses of Mirzam

  • May help support short-term sedation prior to procedures.
  • Used to provide relief from anxiety before operations.
  • Applied to support the induction of general anesthesia.

Mirzam is a prescription medication utilized in hospital or clinic environments to address specific medical requirements. The primary application of this product is to help induce a state of relaxation and reduced awareness, which supports medical or surgical procedures. It is used as a component of anesthetic protocols to prepare patients for the induction of general anesthesia.

In contexts requiring monitored care, Mirzam may be employed to support short-term sedation, assisting patients in remaining calm and still during diagnostic tests or minor procedures. It also serves as a premedication to provide relief from anxiety and apprehension prior to surgical operations. This use aims to help patients achieve a state of emotional stability before entering a procedure.

This medication is not intended for long-term use and its use is limited to professional medical settings.

Eligibility and Restrictions for Use

The use of Mirzam (Desogestrel) is defined by strict regulatory population-eligibility rules. The primary eligible population includes women of childbearing potential, including post-menarche adolescents, for contraception. Conversely, the medication is not indicated for post-menopausal women.


Absolute Contraindications

Mirzam must not be used by individuals with specific health conditions, as defined by official labeling. These absolute contraindications include active venous thromboembolic disorder (such as DVT or PE), severe liver disease where function has not returned to normal, and known or suspected hormone-sensitive malignancies (e.g., breast cancer). Use is also prohibited during a known or suspected pregnancy and in cases of undiagnosed abnormal genital bleeding or known hypersensitivity to the components.


Conditional Use and Restrictions

While the drug is generally considered acceptable during lactation/breastfeeding, certain conditions require caution. Use is not established in patients with renal impairment, as clinical studies are lacking. Caution is also necessary for individuals with less severe hepatic insufficiency. Furthermore, women with a tendency to develop chloasma (melasma) should avoid sun or UV exposure while using the medication.

What should I know about interactions with other medicines?

The active ingredient in Mirzam undergoes metabolism primarily through the Cytochrome P450 3A4 (CYP3A4) enzyme system. This reliance establishes the product's major pharmacokinetic interactions. Co-administration with strong CYP3A4 inhibitors is officially classified as contraindicated by regulatory agencies due to a significant reduction in the drug’s plasma clearance, which substantially increases the risk of prolonged and profound effects.

Interaction Category Outcome on Mirzam Exposure
Strong CYP3A4 Inhibitors Clearance is reduced; exposure is substantially increased (e.g., ketoconazole, ritonavir).
CYP3A4 Inducers Clearance is increased; exposure is markedly decreased (e.g., rifampin, St. John's Wort).
CNS Depressants (Pharmacodynamic) Additive effect; risk of severe sedation and respiratory compromise (e.g., opioids, alcohol).

A separate pharmacodynamic interaction is documented with substances that depress the central nervous system, including opioids and alcohol, where co-use is associated with an elevated risk of hypoventilation and profound sedation. The official labeling also restricts co-ingestion with grapefruit juice, which inhibits intestinal CYP3A4 and increases peak plasma concentrations. Furthermore, the official labeling notes that patients with hepatic or renal impairment may exhibit reduced drug clearance, a condition that functionally results in a prolonged drug effect.

Mechanism of Action

Mirzam functions as a tetracyclic compound that primarily operates through multiple receptor antagonisms within the central nervous system. Its core mechanism involves inhibiting presynaptic alpha2-adrenergic autoreceptors and heteroreceptors. This blockade disinhibits the release of the neurotransmitters norepinephrine and serotonin into the synaptic cleft.

In addition to enhancing the availability of these monoamines, Mirzam acts as a potent antagonist at postsynaptic 5-HT2 and 5-HT3 serotonin receptors. By selectively blocking these sites, the increased serotonin is channeled to interact preferentially with 5-HT1 receptors, specifically the 5-HT1A subtype. This targeted modulation of the serotonergic system represents a key pathway consequence.

Furthermore, the compound exhibits strong antagonistic affinity for Histamine ( H1) receptors, leading to a distinct downstream effect on general central nervous system activity. Mirzam does not inhibit the reuptake of norepinephrine or serotonin, distinguishing its pharmacodynamic profile from that of reuptake inhibitors.

Dosage and Administration Information

Instruction Map: How to use Mirzam

Administration Scope

Instruction Detail
Route of administration Oral (swallowed with liquid).
Dosing schedule One 75 microgram tablet taken daily.
Timing in relation to meals (if applicable) Not dependent on food; should be taken at about the same time each day.
Preparation requirements (if applicable) None; the film-coated tablet must be swallowed whole.
Age-group administration rules Suitable for women who have reached menarche; can be used by breastfeeding women.
Missed-dose rules If less than 12 hours late, take the tablet immediately. If more than 12 hours late, additional barrier contraception is required for the next 7 days.
Special procedural conditions The first pack is typically started on Day 1 of the menstrual cycle; a new pack must be started immediately without any tablet-free interval.

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily and Continuous (28-day packs)
Use-context constraints Time-critical administration (maximum 12-hour allowance for delay) and Cyclical continuity (no break between packs).

Resulting Procedural Structure

The use protocol for Mirzam follows a specific sequence:

  • The daily dose is one 75 microgram tablet, taken orally.
  • The tablet must be consumed at approximately the same time every day, maintaining a 24-hour dosing interval.
  • Upon completing a 28-day pack, the user must immediately start the next pack on the following day without a scheduled break.
  • If a dose is missed, a recovery procedure must be followed: immediate administration of the missed tablet is required if the delay is under 12 hours; otherwise, a barrier method must be introduced for the following 7 days.

Connection to the Overall Use Protocol

The instructions establish a continuous daily regimen that prioritizes consistent progestin exposure over a prolonged period. This structured usage, governed by strict 24-hour timing and the absence of tablet-free days, dictates the necessary procedural steps for initiation, maintenance, and handling of administration errors.

Recent Clinical Evidence

Research evidence / Overview of studies for Mirzam

Evidence Base for Contraception and Pregnancy Prevention

The most extensive and well-established body of research for Mirzam (Desogestrel) relates to its role in contraception. Large-scale Randomized Controlled Trials (RCTs) and observational studies have been applied in studies examining the medicine's role in preventing pregnancy. Researchers examined large groups of healthy women of reproductive age, with studies monitoring various outcomes over defined time intervals.

These studies monitored key outcomes, including the overall rate of unintended pregnancy and hormonal evidence of ovulation inhibition. Research describes findings where consistent daily use was associated with a low rate of pregnancy. This finding contributes to the broader evidence used to evaluate contraceptive research. Studies also explored secondary patterns, such as how menstrual bleeding patterns evolved in the observed populations, reporting findings related to shifts toward irregular bleeding or an absence of bleeding (amenorrhea). This evidence contributes to the broader understanding of how this specific type of progestogen-only pill was observed in the studies.

Research Landscape for Short-Term Sedation and Anesthetic Support

The research context for Mirzam's stated uses in pre-procedure anxiety relief and short-term sedation presents a different landscape. Researchers have extensively conducted Randomized Controlled Trials (RCTs) to examine outcomes related to anxiety and sedation, such as measuring anxiety reduction scores and the time needed to achieve adequate sedation for procedures.

However, when focusing specifically on Mirzam (Desogestrel) itself, there are no dedicated, published regulatory research findings available in authoritative sources, such as major national or intergovernmental health agencies. Research that explores the clinical scenarios of sedation and pre-procedure anxiolysis primarily applies to other pharmacological classes of medicines, meaning research in this area remains insufficient, and evidence dedicated to Mirzam is limited or not available.

Long-Term Evidence and Durability of Study Findings

Research has explored various follow-up durations for Mirzam in the context of contraception. Efficacy research was conducted over intermediate periods, typically equivalent to one year or more of use, which helps contextualize the performance patterns observed in these studies. For certain long-term outcomes, such as the potential impact on specific health conditions, research extends into long-term observational settings, tracking usage patterns over many years.

Frequently Asked Questions (FAQ)

Common questions about Mirzam (FAQ)


Q: How quickly does Mirzam usually start to work?

According to the official protocol for starting Mirzam, if the first tablet is taken between Day 1 and Day 5 of the menstrual cycle, contraceptive protection is expected immediately. If the tablet is started at any other time, official documents advise using a backup barrier method for the first two days of use.


Q: What are the most common reasons people stop taking Mirzam?

Official documentation outlines criteria under which medical oversight may lead to discontinuation, such as the development of thrombosis or sustained, unresponsive high blood pressure. Less serious but common adverse effects, particularly changes in menstrual bleeding patterns, are frequently observed in users.


Q: Is Mirzam known to cause weight gain?

Yes, official regulatory labeling lists weight increase as a common adverse reaction associated with Mirzam use. This effect is documented to affect up to 10 in 100 users.


Q: Is it normal to feel a change in appetite after starting Mirzam?

While a specific change in appetite is not explicitly listed as a categorized side effect in the official documents, common adverse reactions do include nausea and weight increase. These are effects that may sometimes be experienced in association with appetite changes.


Q: How does Mirzam interact with birth control pills?

Mirzam is itself a type of birth control pill (a Progestogen-Only Pill). Official documents state that co-use of Mirzam with other combined hormonal contraceptives (containing both estrogen and progestogen) is not the established use protocol.


Q: Can Mirzam cause 'brain fog' or difficulty concentrating?

Effects specifically described as 'brain fog' or 'difficulty concentrating' are not classified in the official table of adverse reactions. However, official labeling does list common side effects related to the central nervous system, such as headache and changes in mood.


Q: What is the official safety classification of Mirzam (e.g., in pregnancy)?

Official guidance states that Mirzam is contraindicated (must not be used) during a known or suspected pregnancy. While the active ingredient is classified by some regulators to indicate use by a limited number of women without observed fetal harm, certainty based on extensive human data is not established.


Q: Can Mirzam cause high blood pressure?

While high blood pressure (hypertension) is not listed as a common adverse reaction, official documentation notes that if sustained hypertension develops, it is a documented reason for medical review of continued use.


Q: What happens when you stop taking Mirzam?

Official information confirms that the contraceptive effect of the drug ceases upon discontinuation. Following the cessation of Mirzam, fertility is expected to return to the pre-treatment state quickly.


Q: What is the risk of a serious allergic reaction to Mirzam?

Official labeling lists hypersensitivity to the drug’s components as a contraindication. Serious hypersensitivity reactions, such as angioedema (swelling beneath the skin), are noted in the official documentation, but the exact frequency of a generalized serious allergic reaction is not explicitly categorized in the official summary of product characteristics.


Q: What type of monitoring is required when starting Mirzam?

Official guidance describes that patients can expect a healthcare provider to take a thorough medical history and conduct an examination before the initial prescription. Regular check-ups are generally recommended, based on established medical practice.


Q: Does Mirzam affect cholesterol levels?

Regulatory documents note that the use of this medication can be associated with documented changes to certain serum lipid parameters, including triglycerides and cholesterol levels, as observed in studies.


Q: Is Mirzam a narcotic or a controlled substance?

Mirzam is an oral contraceptive and is not classified as a controlled substance under the U.S. Controlled Substances Act (CSA) or similar international drug scheduling laws.


Q: What kind of fatigue or drowsiness is associated with Mirzam?

Official documentation lists fatigue as an uncommon adverse reaction, meaning it is documented to affect between 1 and 10 in 1,000 users. Drowsiness itself is not specifically listed as a common adverse reaction in the labeling.


Q: Can Mirzam be taken with pain relievers like Tylenol (acetaminophen)?

Regulatory documentation does not list a specific contraindication or warning for the co-administration of Mirzam (Desogestrel) and acetaminophen. This indicates there is no formally classified major or moderate interaction between the two medications.


Q: Are there any foods or drinks to avoid while taking Mirzam?

Official warnings note that certain substances that inhibit the CYP3A4 enzyme should be avoided. This specifically includes grapefruit juice, as it can increase the concentration of the active substance in the body.


Q: Does Mirzam affect sleep patterns?

The official list of adverse reactions does not contain specific disturbances to sleep patterns like insomnia or vivid dreams. However, general adverse effects related to the central nervous system, such as headache and mood changes, are listed.


Q: Can Mirzam cause changes in mood or emotional state?

Official regulatory labeling lists changes in mood, including depressed mood, as a common adverse reaction. This is documented to affect between 1 and 10 in 100 users.


Q: Is it safe to drive or operate machinery after taking Mirzam?

Official guidance explicitly indicates that Mirzam is not expected to have an influence on the ability to drive or use machinery.


Q: Is there a generic version of Mirzam available?

The active ingredient in Mirzam is Desogestrel, which is widely available from various manufacturers globally. Multiple generic versions of this compound have been approved by various national regulatory bodies.


Q: Is Mirzam commonly used for conditions other than its main purpose?

Official regulatory documents only list contraception (prevention of pregnancy) as the approved therapeutic indication for this product.


Q: Can Mirzam be taken with over-the-counter cold and flu medicines?

Regulatory documentation warns about combining Mirzam with central nervous system (CNS) depressants. Given that some cold and flu medicines contain these ingredients, caution related to potential additive effects is noted.


Q: Why is it important to inform a doctor about all supplements before starting Mirzam?

This is important because official documentation warns that certain herbal supplements, such as St. John’s Wort, can interfere with Mirzam’s effectiveness. These supplements may reduce the concentration of Mirzam in the body, potentially compromising the drug’s primary function.

How should Mirzam be stored and disposed of?

How to Store and Dispose of Mirzam

Mirzam (Desogestrel) must be stored and handled according to specific regulatory requirements to maintain its stability and effectiveness.

Storage Conditions

Mirzam should be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture and should be kept in its original package (blister in outer carton) until use. It is crucial that the medicine is kept out of the sight and reach of children.

Handling and Disposal

Do not refrigerate or freeze the tablets. Do not use the product after the stated expiration date. Any unused or expired Mirzam must be disposed of in accordance with local requirements for pharmaceutical waste. The product must not be thrown into household trash or wastewater (sewage) due to documented environmental risk.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mirzam found in:

A-Z Index: